COVID-19：在俄罗斯待售的新电晕疗法：“Coronavir”
俄罗斯药房：
基于日本流感药物“ Avigan”，已经开始销售一种新的冠状病毒药物。
电晕大厦：
在俄罗斯，9月21日开始销售两种俄罗斯制造的治疗剂，例如“ Coronavir”。
Coronavir 50片的售价约为18,000日元。
购买时需要医生处方。
药房经理：（问：有效吗？）
它在新电晕的早期和中期有效。
Coronavir是日本Fujifilm Toyama Chemical Co.，Ltd.开发的新型流感药物“ Avigan”的仿制药。
一家俄罗斯制造商评论说：“超过一半的接受这种药物治疗的患者在一周内改善了症状。”
https://news.tv-asahi.co.jp/news_international/articles/000193741.html
Russia Health Ministry Allows Use of Favipiravir for Outpatient COVID-19 Use
Back on June 1, TrialSite reported that Russian regulators approved a version of favipiravir known as Avifavir for hospitalized patients.
Now the Russian Healthcare Ministry has approved the use of two favipiravir-based preparations for outpatient treatment for the SARS-CoV-2 indication.
Russi Russian Approvals
Recently, Russia’s Tass shared with the world the update to Favipiravir status in that country.
Russia
has achieved technically two firsts since the onset of pandemic.
In May, the regulators there approved the Favipiravir version called Avifavir making it the world’s first approved therapy targeting COVID-19, according to Tass.
Of course, months later Russia also was the first to actually certify a vaccine, albeit in an unorthodox manner.
a Health Ministry Allows Use of Favipiravir for Outpatient COVID-19 Use